Skip to content

Bicara Therapeutics BCAX Other operating expenses

Other operating expenses at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$46.11M-30.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$151M+0.7%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$99.07M-4.6%
Nuvation Bio logo
Nuvation BioNUVB
$79.35M+27.8%
Erasca, Inc. logo
Erasca, Inc.ERAS
$187.91M+427%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$159.55M+40.2%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's other operating expenses?
Bicara Therapeutics (BCAX) reported other operating expenses of 6,024,200,000% in Q1 2026.
How has Bicara Therapeutics's other operating expenses changed year-over-year?
Bicara Therapeutics's other operating expenses increased by 44.2% year-over-year, from 4,178,800,000% to 6,024,200,000%.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.